efficacy of Duloxetine for prevention of chemotherapy induced neuropathy
Phase 2
- Conditions
- breast cancer.Malignant neoplasm of breast
- Registration Number
- IRCT2016050227711N1
- Lead Sponsor
- Breast Cancer Research Center of Jahad Daneshgahi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 116
Inclusion Criteria
inclusion criteria:
-patient receiving paclitaxel
-it is the first dose of paclitaxel
-prior or ongoing treatment with other neurotoxic chemotherapic agents is not allowed
-participants with out any documented medical history of nerve compression, leptomeningeal carcinomatosis, severe depression, suicidal idea, bipolar disease, alcohol abuse, glaucoma, diabetes, thyroid abnormality, markedly abnormal renal or liver function tests
- not taking any medicine interfere in serotonin level
-not taking any analgesic medicine routinely in two weeks before entering the trial
exclusion criteria:
-sever complications with duloxetine
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method europathy. Timepoint: before satrting intervention and 6-12-24 weeks after that. Method of measurement: NCI-CTCAE and FACT-TAXAN questionnaire.
- Secondary Outcome Measures
Name Time Method Quality of life. Timepoint: before starting intervention and in 6-12-24 weeks after that. Method of measurement: FACT-TAXAN questionnaire.